| Item Type | Name |
|
Concept
|
Administration, Topical
|
|
Concept
|
Administration, Cutaneous
|
|
Concept
|
Administration, Oral
|
|
Concept
|
United States Food and Drug Administration
|
|
Concept
|
Drug Administration Schedule
|
|
Academic Article
|
Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A.
|
|
Academic Article
|
Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial.
|
|
Academic Article
|
Cyclosporin for severe ulcerative colitis: a user's guide.
|
|
Academic Article
|
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group.
|
|
Academic Article
|
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease.
|
|
Academic Article
|
Efficacy of parenteral methotrexate in refractory Crohn's disease.
|
|
Academic Article
|
Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
|
|
Academic Article
|
Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies.
|
|
Academic Article
|
Immunogenicity of infliximab in Crohn's disease.
|
|
Academic Article
|
Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
|
|
Academic Article
|
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
|
|
Academic Article
|
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
|
|
Academic Article
|
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
|
|
Academic Article
|
The state of the art in the management of inflammatory bowel disease.
|
|
Academic Article
|
Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease.
|
|
Academic Article
|
Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down".
|
|
Academic Article
|
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
|
|
Academic Article
|
Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study.
|
|
Academic Article
|
Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
|
|
Academic Article
|
Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
|
|
Academic Article
|
Aminosalicylates: old and new.
|
|
Academic Article
|
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
|
|
Academic Article
|
Where do our priorities lie?
|
|
Academic Article
|
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.
|
|
Academic Article
|
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
|
|
Academic Article
|
Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis.
|
|
Academic Article
|
Treatment of Crohn's disease: the "long" of it.
|
|
Academic Article
|
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
|
|
Academic Article
|
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
|
|
Academic Article
|
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.
|
|
Academic Article
|
Nicotine for colitis--the smoke has not yet cleared.
|
|
Academic Article
|
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
|
|
Academic Article
|
Mesalamine capsules enhance the quality of life for patients with ulcerative colitis.
|
|
Academic Article
|
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
|
|
Academic Article
|
Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
|
|
Academic Article
|
Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
|
|
Academic Article
|
Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
|
|
Academic Article
|
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center.
|
|
Academic Article
|
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
|
|
Academic Article
|
Vedolizumab as induction and maintenance therapy for Crohn's disease.
|
|
Academic Article
|
Oral or Topical 5-ASA in Ulcerative Colitis.
|
|
Academic Article
|
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
|
|
Academic Article
|
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
|
|
Concept
|
Administration, Intravenous
|
|
Academic Article
|
Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease.
|